Tandem Diabetes Care Enters Multi-Year Research Collaboration with the UVA 

Tandem Diabetes Care, Inc. has signed a multi-year collaboration agreement with the University of Virginia Center for Diabetes Technology (UVA) to advance research and development efforts on fully automated closed-loop insulin delivery systems.

Tandem will provide research funding, technology, and supplies to the University of Virginia during the agreement term for diabetes-centered research and potential clinical studies.

“Our past work with UVA, including research related to our automated insulin delivery systems as part of the International Diabetes Closed Loop trials, helped contribute to life-changing products for the diabetes community,” said John Sheridan, president and chief executive officer at Tandem.  “We believe this research collaboration will continue on our joint history of delivering new innovations that can further improve the lives of people living with diabetes.”

The research will build on Tandem’s ongoing research into the advancement of automated closed-loop insulin delivery technology. The collaboration will rely on the UVA Center for Diabetes Technology’s successes in translating advanced automated insulin delivery (AID) algorithms into medical devices used around the world. It will also leverage Tandem’s market-leading expertise in insulin delivery devices, algorithm implementation, and data management.

Research will involve scientists, clinicians, and functional experts from both institutions. Results from this collaboration may lead to clinical research to accelerate approved uses for Tandem’s next-generation AID systems.

“After more than 10 years working with the Tandem team, this is an exciting new beginning for our collaboration to serve patients with diabetes,” said Marc Breton, PhD, associate director for research at the UVA Center for Diabetes Technology. “Together, we will expand our research efforts into automated insulin delivery with the goal of once more substantially enhancing care and quality of life for patients around the world.”